Novartis news from FierceBiotech
NewsTraditional remedies offer opportunities, challenges
The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...
ALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...
> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company. Read more...
Novartis' China plans grew from science roundtables
PharmAsia News sat down with Paul Herrling, head of corporate research at Novartis, and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, to discuss the Read more...
Novartis reports strong meningitis vaccine response
In a head-to-head trial, researchers for Novartis say that the experimental meningitis vaccine Menveo produced a more potent immune response than the standard therapy in use. And other data has Read more...
Paratek funds Phase III launch with $40M in VC
Paratek Pharmaceuticals has closed the second tranche on its $40 million round of venture funding. The money allows the Boston-based developer to launch a Phase III trial of the experimental Read more...
SPOTLIGHT: Novartis touts new MS data
Researchers at Novartis say that after three years of therapy in an ongoing Phase II study, the oral FTY720 demonstrated positive results for patients with multiple sclerosis. Data demonstrate that Read more...
Aileron, Heritage Pharma each raise $10M in VC
Novartis Venture Funds and Apple Tree Partners have teamed up to lead a $10 million venture round for Cambridge, MA-based Aileron Therapeutics. Aileron says it will use much of the money to expand Read more...
Antisoma starts licensing spree with cancer deal
Bankrolled by a $125 million licensing deal with Novartis, the UK's Antisoma has turned around and used part of its Read more...
Novartis CEO: Deals possible in diagnostics, vaccines
Novartis AG CEO Daniel Vasella (photo) concedes that his company is going through a rough stage, but insists that a Read more...
SPOTLIGHT: Novartis taps new U.S. pharma chief
The musical chairs game in Novartis' top management ranks is continuing as new pharma chief Joe Jiminez revamps the ranks. The Swiss drug maker has appointed Ludwig Hantson to top its U.S. Read more...
| Press ReleasesNew data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants Data in JAMA show Menveo may provide infants protection against four of the most common Read more... PRESS RELEASE: Novartis launches strategic initiative to improve competitiveness in a changing healthcare environmenT Novartis launches strategic initiative to improve competitiveness in a dynamically changing healthcare environment "Forward" to simplify organizational structures, accelerate and Read more... PRESS RELEASE: Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Collaboration efforts will focus on the discovery and optimization of antibodies against a significant Read more... PRESS RELEASE: Tasigna gains European approval for patients with a life-threatening form of leukemia who are resistant or intol Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies Tasigna produced response in 49% of patients with Read more... PRESS RELEASE: Antisoma Shares Slide as Novartis Corporation (NVS) Sets up Avastin Fight Antisoma Shares Slide as Novartis Corporation Sets up Avastin Fight LONDON--Nov 20, 2007 -- ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Read more... |
Get more Novartis coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight